SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

Dami A. Collier1,2,3,*, Anna De Marco4,*, Isabella A.T.M. Ferreira1,2 Bo Meng1,2,*, Rawlings Datir1,2,3, Alexandra C. Walls3, Steven A. Kemp1,2,3, Jessica Bassi4, Dora Pinto4, Chiara Silacci Fregni4, Siro Bianchi4, M. Alejandra Tortorici5, John Bowen3, Katja Culap4, Stefano Jaconi4, Elisabetta Cameroni4, Gyorgy Snell6, Matteo S. Pizzuto4, Alessandra Franzetti Pellanda7, Christian Garzoni7, Agostino Riva8, The CITIID-NIHR BioResource COVID-19 Collaboration9, Anne Elmer10, Nathalie Kingston11, Barbara Graves11, Laura E McCoy9, Kenneth GC Smith1,2, John R. Bradley2,11, Nigel Temperton12, Lourdes Ceron-Gutierrez L13, Gabriela Barcenas-Morales13,14, The COVID-19 Genomics UK (COG-UK) consortium15, William Harvey16, Herbert W. Virgin6, Antonio Lanzavecchia4, Luca Piccoli4, Rainer Doffinger1,2, Mark Wills2, David Veesler5, Davide Corti4,*, Ravindra K. Gupta1,17,18,19,*. 
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
2Department of Medicine, University of Cambridge, Cambridge, UK.
3Division of Infection and Immunity, University College London, London, UK.
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
5Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
6Vir Biotechnology, San Francisco, CA 94158, USA.
7Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland
8Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy
9The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix 1 for author list
10NIHR Cambridge Clinical Research Facility, Cambridge, UK.
11NIHR Bioresource, Cambridge, UK
12University of Kent, Canterbury, UK
13Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK
14Laboratorio de Inmunologia, S-Cuautitlán, UNAM, Mexico
15https://www.cogconsortium.uk. Full list of consortium names and affiliations are in Appendix 2.
16Institute of Biodiversity, University of Glasgow, Glasgow, UK
17University of KwaZulu Natal, Durban, South Africa
18Africa Health Research Institute, Durban, South Africa
19Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge UK.
*Equal contribution

Correspondence: dcorti@vir.bio, rkg20@cam.ac.uk

Key words: SARS-CoV-2; COVID-19; antibody, vaccine, neutralising antibodies; mutation; variant
Abstract
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 out of 31), but not in neutralising mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralising activity by vaccine-elicited antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b2.

Introduction
The outbreak of a pneumonia of unknown cause in Wuhan, China in December 2019, culminated in a global pandemic due to a novel viral pathogen, now known to be SARS-CoV-2. The unprecedented scientific response to this global challenge has led to the rapid development of vaccines aimed at preventing SARS-CoV-2 infection and transmission. Continued viral evolution led to the emergence and selection of SARS-CoV-2 variants with enhanced infectivity/transmissibility and ability to circumvent drug and immune control.

SARS-CoV-2 vaccines have recently been licensed that target the spike (S) protein, either using mRNA or adenovirus vector technology with protection rates ranging from 62 to 95%. The BNT162b2 vaccine encodes the full-length trimerised S protein of SARS CoV-2 and is formulated in lipid nanoparticles for delivery to cells. Other vaccines include the Moderna mRNA-1273 vaccine, which is also a lipid nanoparticle formulated S glycoprotein and the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (AZD1222) which is a replication-deficient chimpanzee adenoviral vector ChAdOx1, containing the S glycoprotein. The duration of immunity conferred by these vaccines is as yet unknown. These vaccines were designed against the Wuhan-1 isolate discovered in 2019. Concerns have been raised as to whether these vaccines will be effective against newly emergent SARS-CoV-2 variants, such
as B.1.1.7 (N501Y.V1), B.1.351 (N501Y.V2) and P1 (N501Y.V3) that originated in the UK, South Africa, and Brazil and are now being detected all over the world\textsuperscript{15-17}. In clinical studies of the Pfizer-BioNTech BNT162b2 vaccine, high levels of protection against infection and severe disease were observed after the second dose\textsuperscript{16}. Neutralising geometric mean titre (GMT) was below cut-off in most cases after prime dose, but as anticipated, titres substantially increased after boost immunization\textsuperscript{18}. In older adults mean GMT was only 12 in a preliminary analysis of 12 participants\textsuperscript{19} and increased to 109 after the second dose.

In this study, we assess antibody responses against the the B.1.1.7 variant after vaccination with the first and second doses of BNT162b2, showing modest reduction in neutralisation against pseudoviruses bearing B.1.1.7 Spike mutations (\textDelta H69/V70, \textDelta 144, N501Y, A570D, P681R, T716I, S982A and D1118H). In addition, by using a panel of human neutralising monoclonal antibodies (mAbs) we show that the B.1.1.7 variant can escape neutralisation mediated by most NTD-specific antibodies tested and by a fraction of RBM-specific antibodies. Finally, we show that the recent emergence and transmission of B.1.1.7 viruses bearing the Spike E484K mutation results in significant additional loss of neutralisation by BNT162b2 mRNA-elicited antibodies, convalescent sera and mAbs.

\section*{Results}

Thirty seven participants had received the first dose of BNT162b2 mRNA vaccine three weeks prior to blood draw for serum and peripheral blood mononuclear cells (PBMC) collection. Median age was 63.5 years (IQR 47-84) and 33\% were female. Serum IgG titres to Nucleocapsid (N) protein, S and the S receptor binding domain (RBD) were assayed by particle based flow cytometry on a Luminex analyser (Extended Data Fig. 1a). These data showed S and RBD antibody titres much higher than in healthy controls, but lower than in individuals recovered from COVID-19 and titres observed in therapeutic convalescent plasma. The raised N titres relative to control could be the result of non-specific cross reactivity that is increased following vaccination. However, the antibody response was heterogeneous with almost 100-fold variation in IgG titres to S and RBD across the vaccinated participants.

Using lentiviral pseudotyping we studied WT (wild type bearing D614G) and mutant B.1.1.7 S proteins (Fig. 1a) on the surface of enveloped virions in order to measure neutralisation activity of vaccine-elicited sera. This system has been shown to give results correlating with replication competent authentic virus\textsuperscript{20,21}. Eight out of 37 participants exhibited
no appreciable neutralisation against the WT pseudotyped virus following the first dose of vaccines. The vaccine sera exhibited a range of inhibitory dilutions giving 50% neutralisation (ID50) (Fig. 1c-d). The GMT against wild type (WT) following the second dose of vaccine was an order of magnitude higher than after the first dose (318 vs 77) (Fig 1c-f). There was correlation between full length S IgG titres and serum neutralisation titres (Extended Data Fig. 1b). A broad range of T cell responses was measured by IFN gamma FluoroSpot against SARS-CoV-2 peptides in vaccinees. These cellular responses did not correlate with IgG S antibody titres (Extended Data Fig. 1c-d).

We then generated mutated pseudoviruses carrying S protein with mutations N501Y, A570D and the H69/V70 deletion. We observed no reduction in the ability of sera from vaccinees to inhibit either WT or mutant virus (Extended Data Fig. 2a, b). A panel of sera from ten recovered individuals also neutralised both wild type and the mutated viruses similarly (Extended Data Fig. 2c). We next completed the full set of eight mutations in the S protein present in B.1.1.7 variant (Fig. 1a), ΔH69/V70, Δ144, N501Y and A570D in the S1 subunit and P681H, T716I, S982A and D1118H in the S2 subunit. All constructs also contained D614G. We found that among 29 individuals with neutralisation activity against the WT three weeks after receiving a single dose of the the BNT162b2 mRNA vaccine, 20 showed evidence of reduction in efficacy of antibodies against the B.1.1.7 mutant (Fig. 1b-c, Extended Data Fig. 3). The mean fold change reduction in sensitivity to first dose vaccine sera of B.1.1.7 compared to WT was approximately 3.2 (SD 5.7). The variation is likely due to the low neutralisation titres following first dose. Following the second dose, GMT was markedly increased compared with first dose titres, and the mean fold change had reduced to 1.9 (SD 0.9) (Fig. 1d-e). Amongst sera from 27 recovered individuals, the GMT at 50% neutralisation was 1334 for WT, significantly higher than post second dose vaccination (Fig. 1f-g). The fold change in ID50 for neutralisation of B.1.1.7 versus wild type (D614G) was 4.5 (Fig. 1f-g and Extended Data Fig. 4).

**B.1.1.7 with spike E484K mutation and neutralization by vaccine and convalescent sera**

The E484K substitution (Fig. 2a) is antigenically important, and has been reported as an escape mutation for several monoclonal antibodies including C121, C144, REGN10933 and Ly-CoV555. E484K is also known to be present in the B.1.351 (501Y.V2) and P.1 (501Y.V3) lineages in combination with amino acid replacements at N501 and K417. As of 10th Feb 2021, twenty three English and two Welsh B.1.1.7 sequences from viral isolates contained the E484K
The number of B.1.1.7 sequences has been increasing since the start of December 2020 (Fig. 2c). Phylogenetic analysis suggests that there have been multiple independent acquisitions, with one lineage appearing to expand over time, indicating active transmission (Fig. 2b). This has resulted in Public Health England naming this as a variant of concern (VOC 202102/02)\textsuperscript{23}, triggering enhanced public health measures. There are as yet no phenotypic data on the sensitivity to neutralisation for this virus or its spike protein.

We therefore generated pseudoviruses bearing B.1.1.7 spike mutations with or without additional E484K and tested these against sera obtained after first and second dose mRNA vaccine as well as against convalescent sera. Following second dose, we observed a significant loss of neutralising activity for the pseudovirus with B.1.1.7 spike mutations and E484K (Fig 3d-e). The mean fold change for the E484K B.1.1.7 Spike was 6.7 compared to 1.9 for B.1.1.7, relative to WT (Fig. 3a-c). Similarly when we tested a panel of convalescent sera with a range of neutralisation titres (Fig. 1f-g), we observed additional loss of activity against the mutant B.1.1.7 spike with E484K, with fold change of 11.4 relative to WT (Fig. 3f-g).

**B.1.1.7 variant escape from NTD- and RBM-specific mAb-mediated neutralization.**

To investigate the role of the full set of mutations in NTD, RBD and S2 present in the B.1.1.7 variant, we tested 60 mAbs isolated from 15 individuals that recovered from SARS-CoV-2 infection in early 2020 with an in-vitro pseudotyped neutralization assay using VeroE6 target cells expressing Transmembrane protease serine 2 (TMPRSS2, Extended Data Table 1). We found that 20 out of 60 (33.3\%) mAbs showed a greater than 2-fold loss of neutralising activity of B.1.1.7 variant compared to WT SARS-CoV-2 (Fig. 4a,b and Extended Data Fig. 5). Remarkably, the B.1.1.7 mutant virus was found to fully escape neutralization by 8 out of 10 NTD-targeting mAbs (80\%), and partial escape from an additional mAb (10\%) (Fig. 4c).

We previously showed that the deletion of residue 144 abrogates binding by 4 out of 6 NTD-specific mAbs tested, possibly accounting for viral neutralization escape by most NTD-specific antibodies\textsuperscript{24}. Of the 31 RBD-targeting mAbs, 5 (16.1\%) showed more than 100-fold decrease in B.1.1.7 neutralization, and additional 6 mAbs (19.4\%) had a partial 2-to-10-fold reduction (Fig. 4d). Finally, all RBD-specific non-RBM-targeting mAbs tested fully retained B.1.1.7 neutralising activity (Fig. 4e).

To address the role of B.1.1.7 N501Y mutation in the neutralization escape from RBM-specific antibodies, we tested the binding of 50 RBD-specific mAbs to WT and N501Y mutant RBD by biolayer interferometry (Fig. 4f and Extended Data Fig. 6). The 5 RBM-specific
mAbs that failed to neutralize B.1.1.7 variant (Fig. 4d) showed a complete loss of binding to N501Y RBD mutant (Fig. 4g-h), demonstrating a role for this mutation as an escape mechanism for certain RBM-targeting mAbs.

The decreased neutralising activity of the immune sera from vaccinees and convalescent patients against B.1.1.7, but not against $\Delta 69/70$-501Y-570D mutant (Fig. 1 and Extended Data Fig. 2), could be the result of a loss of neutralising activity of both RBD- and NTD-targeting antibodies, and suggests that the key mutation is $\Delta 144$. RBD antibodies against N501Y could play a role in decreased neutralisation by sera, with the overall impact possibly modulated by other mutations present in B.1.1.7, as well as the relative dominance of NTD versus RBM antibodies in polyclonal sera.

To assess the effect of E484K on this panel of mAbs we generated a SARS-CoV-2 pseudotype carrying the K417N, E484K and N501Y mutations (TM). The inclusion of the K417N substitution was prompted by the observation that substitutions at this position have been found in 5 sequences from recent viral isolates within the B.1.1.7 lineage (K417 to N, E or R). This is in keeping with convergent evolution of the virus towards an RBD with N501Y, E484K and K417N/T as evidenced by B.1.351 and P.1 lineages (K417N or K417T, respectively) causing great concern globally. It is therefore important to assess this combination going forward.

Importantly, mutations at K417 are reported to escape neutralization from mAbs, including the recently approved mAb LY-CoV016.22 Out of the 60 mAbs tested, 20 (33.3%) showed >10 fold loss of neutralising activity of TM mutant compared to WT SARS-CoV-2 (Fig. 4a-b and Extended Data Fig. 5), and of these 19 are RBM-specific mAbs. As above, we addressed the role of E484K mutation in escape from RBM-specific antibodies, by testing the binding of 50 RBD-specific mAbs to WT and E484K mutant RBD by biolayer interferometry (Fig. 4f and Extended Data Fig. 7). Out of the 19 RBM-specific mAbs that showed reduced or loss of neutralization of TM mutant (Fig. 4d), 16 showed a complete or partial loss of binding to E484K RBD mutant (Fig. 4g-h), consistent with findings that E484K is an important viral escape mutation.26,39,27 Three of these 16 mAbs also lost binding to an RBD carrying N501Y, indicating that a fraction of RBM antibodies are sensitive to both N501Y and E484K mutations. Similarly, 3 of the 19 mAbs that lost neutralization of TM mutant (S2D8, S2H7 and S2X128) were previously shown to lose binding and neutralization to the K417V mutant, and here shown to be sensitive to either N501Y or E484K mutations.

SARS-CoV-2 B.1.1.7 binds human ACE2 with higher affinity than WT
SARS-CoV-2 and SARS-CoV enter host cells through binding of the S glycoprotein to angiotensin converting enzyme 2 (ACE2)\(^1\,\text{,}\,\text{28}\). Previous studies showed that the binding affinity of SARS-CoV for human ACE2 correlated with the rate of viral replication in distinct species, transmissibility and disease severity\(^29\,\text{–}\,\text{31}\). However, the picture is unclear for SARS-CoV-2. To understand the potential contribution of receptor interaction to infectivity, we set out to evaluate the influence of the B.1.1.7 RBD substitution N501Y on receptor engagement. We used biolayer interferometry to study binding kinetics and affinity of the purified human ACE2 ectodomain (residues 1-615) to immobilized biotinylated SARS-CoV-2 B.1.1.7 or WT RBDs. We found that ACE2 bound to the B.1.1.7 RBD with an affinity of 22 nM compared to 133 nM for the WT RBD (Extended Data Fig. 8), in agreement with our previous deep-mutational scanning measurements using dimeric ACE2\(^32\). Although ACE2 bound with comparable on-rates to both RBDs, the observed dissociation rate constant was slower for B.1.1.7 than for the WT RBD (Table 1).

To understand the impact of TM mutations (K417N, E484K and N501Y), we evaluated binding of ACE2 to the immobilized TM RBD using biolayer interferometry. We determined an ACE2 binding affinity of 64 nM for the TM RBD which is driven by a faster off-rate than observed for the B.1.1.7 RBD but slower than for the WT RBD. Based on our previous deep-mutational scanning measurements using dimeric ACE2, we propose that the K417N mutation is slightly detrimental to ACE2 binding explaining the intermediate affinity determined for the TM RBD compared to the B.1.17 and WT RBDs, likely as a result of disrupting the salt bridge formed with ACE2 residue D30. Enhanced binding of the B.1.1.7 RBD to human ACE2 resulting from the N501Y mutation might participate in the efficient ongoing transmission of this newly emergent SARS-CoV-2 lineage, and possibly reduced opportunity for antibody binding. Although the TM RBD mutations found in B.1.351 are known to participate in immune evasion\(^33\,\text{,}\,\text{34}\), the possible contribution to transmissibility of enhanced ACE2 binding relative to WT remains to be determined for this lineage.
Discussion

Serum neutralising activity is a correlate of protection for other respiratory viruses, including influenza and respiratory syncytial virus where prophylaxis with monoclonal antibodies has been used in at-risk groups. Neutralising antibody titres appeared to be highly correlated with vaccine protection against SARS-CoV-2 rechallenge in non-human primates, and importantly, there was no correlation between T cell responses (as measured by ELISpot) and protection. Moreover, passive transfer of purified polyclonal IgGs from convalescent macaques protected naïve macaques against subsequent SARS-CoV-2 challenge. Coupled with multiple reports of re-infection, there has therefore been significant attention placed on virus neutralisation.

This study reports on the neutralisation by sera collected after both the first and second doses of the BNT162b2 vaccine. The participants of this study were older adults, in line with the targeting of this age group in the initial rollout of the vaccination campaign in the UK. Participants showed similar neutralising activity against wild type pseudovirus as in the phase I/II study. This is relevant for the UK and other countries planning to extend the gap between doses of mRNA and adenovirus based vaccines from 3 to 12 weeks, despite lack of data for this schedule for mRNA vaccines in particular.

The three mutations in S1 (N501Y, A570D, ΔH69/V70) did not appear to impact neutralisation in a pseudovirus assay, consistent with data on N501Y having little effect on neutralisation by convalescent and post vaccination sera. However, we demonstrated that a pseudovirus bearing S protein with the full set of mutations present in the B.1.1.7 variant (i.e., ΔH69/V70, Δ144, N501Y, A570D, P681H, T716I, S982A, D1118H) did result in small reduction in neutralisation by sera from vaccinees that was more marked following the first dose than the second dose. This could be related to increased breadth/potency/concentration of antibodies following the boost dose. A reduction in neutralization titres from mRNA-elicited antibodies in volunteers who received two doses (using both mRNA-1273 and BNT162b2 vaccines) was also observed by Wang et al. using pseudoviruses carrying the N501Y mutation. Other studies also reported small reduction of neutralization against the B.1.1.7 variant against sera from individuals vaccinated with two doses of BNT162b2 and mRNA-1273. Xie et al did not find an effect of N501Y alone in the context of BNT162b2 vaccine sera.
The reduced neutralising activity observed with polyclonal antibodies elicited by mRNA vaccines observed in this study is further supported by the loss of neutralising activity observed with human mAbs directed to both RBD and, to a major extent, to NTD. In the study by Wang et al., 6 out 17 RBD-specific mAbs isolated from mRNA-1273 vaccinated individuals showed more than 100-fold neutralisation loss against N501Y mutant, a finding that is consistent with the loss of neutralisation by 5 out 29 RBM-specific mAbs described in this study. However, the contribution of N501Y to loss of neutralisation activity of polyclonal vaccine and convalescent sera is less clear, and interactions with other mutations likely.

Multiple variants, including the 501Y.V2 and B.1.1.7 lineages, harbor multiple mutations as well as deletions in NTD, most of which are located in a site of vulnerability that is targeted by all known NTD-specific neutralising antibodies\textsuperscript{24,45}. The role of NTD-specific neutralising antibodies might be under-estimated, in part by the use of neutralization assays based on target cells over-expressing ACE2 receptor. NTD-specific mAbs were suggested to interfere with viral entry based on other accessory receptors, such as DC-SIGN and L-SIGN\textsuperscript{46}, and their neutralization potency was found to be dependent on different in vitro culture conditions\textsuperscript{24}. The observation that 9 out of 10 NTD-specific neutralising antibodies failed to show a complete or near-complete loss of neutralising activity against B.1.1.7 indicates that this new variant may have evolved also to escape from this class of antibodies, that may have a yet unrecognized role in protective immunity. Wibmer et al.\textsuperscript{34} have also recently reported the loss of neutralization of 501Y.V2 by the NTD-specific mAb 4A8, likely driven by the R246I mutation. This result is in line with the lack of neutralization of B.1.1.7 by the 4A8 mAb observed in this study, likely caused by Δ144 due to loss of binding\textsuperscript{24}. Finally, the role of NTD mutations (in particular, L18F, Δ242-244 and R246I) was further supported by the marked loss of neutralization observed by Wibmer et al.\textsuperscript{34} against 501Y.V2 compared to the chimeric pseudotyped viral particle carrying only the RBD mutations K417N, E484K and N501Y. Taken together, the presence of multiple escape mutations in NTD is supportive of the hypothesis that this region of the spike, in addition to RBM, is also under immune pressure.

Worryingly, we have shown that there are multiple B.1.1.7 sequences in the UK bearing E484K with early evidence of transmission as well as independent acquisitions. We measured further reduction neutralisation titers by vaccine sera when E484K was present alongside the B.1.1.7 S mutations. Wu and co-authors\textsuperscript{43} have also shown that variants carrying the E484K mutation resulted in 3-to-6 fold reduction in neutralization by sera from mRNA-1273
vaccinated individuals. Consistently, in this study we found that approximately 50% of the RBM mAbs tested lost neutralising activity against SARS-CoV-2 carrying E484K. E484K has been shown to impact neutralisation by monoclonal antibodies or convalescent sera, especially in combination with N501Y and K417N\textsuperscript{16,26,47-49}. Wang et al also showed reduced neutralisation by mRNA vaccine sera against E484K bearing pseudovirus\textsuperscript{34}.

Evidence for the importance role of NTD deletions in combination with E484K in immune escape is provided by Andreano \textit{et al.}\textsuperscript{27} who describe the emergence of Δ140 in virus co-incubated with potently neutralising convalescent plasma, causing a 4-fold reduction in neutralization titre. This Δ140 mutant subsequently acquired E484K which resulted in a further 4-fold drop in neutralization titre indicating a two residue change across NTD and RBD represents an effective pathway of escape that can dramatically inhibit the polyclonal response.

Our study was limited by modest sample size. Although the spike pseudotyping system has been shown to faithfully represent full length infectious virus, there may be determinants outside the S that influence escape from antibody neutralization either directly or indirectly in a live replication competent system. On the other hand live virus systems allow replication and therefore mutations to occur, and rigorous sequencing at multiple steps is needed.

Vaccines are a key part of a long term strategy to bring SARS-CoV-2 transmission under control. Our data suggest that vaccine escape to current Spike directed vaccines designed against the Wuhan strain will be inevitable, particularly given that E484K is emerging independently and recurrently on a B.1.1.7 (501Y.V1) background, and given the rapid global spread of B.1.1.7. Other major variants with E484K such as 501Y.V2 and V3 are also spreading regionally. This should be mitigated by designing next generation vaccines with mutated S sequences and using alternative viral antigens.

\textbf{Acknowledgements}
We would like to thank Cambridge University Hospitals NHS Trust Occupational Health Department. We would also like to thank the NIHR Cambridge Clinical Research Facility and staff at CUH and. We would like to thank Eleanor Lim and Georgina Okecha. We thank Dr James Voss for the kind gift of HeLa cells stably expressing ACE2. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by
a Medical Research Council Career Development Award (MR/R008698/1). SAK is supported by the Bill and Melinda Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by a Wellcome Trust Clinical PhD Research Fellowship. KGCS is the recipient of a Wellcome Investigator Award (200871/Z/16/Z). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, the Cambridge Clinical Trials Unit (CCTU), and the NIHR BioResource. This study was supported by the National Institute of General Medical Sciences (R01GM120553 to D.V.), the National Institute of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to D.V.), a Pew Biomedical Scholars Award (D.V.), an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (D.V.) and Fast Grants (D.V.). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. JAGB is supported by the Medical Research Council (MC_UP_1201/16). IATM is funded by a SANTHE award.

Author contributions

Conceived study: D.C., RKG, DAC. Designed study and experiments: RKG, DAC, LEM, JB, MW, JT, LCG, GBM, RD, BG, NK, AE, M.P., D.V., L.P., A.D.M, J.B., D.C. Performed experiments: BM, DAC, RD, IATMF, ACW, LCG, GBM. Interpreted data: RKG, DAC, BM, RD, IATMF, ACW, LEM, JB, KGCS, DV. ADM, JB and CSF carried out pseudovirus neutralization assays. DP produced pseudoviruses. MSP, LP, DV and DC designed the experiments. MAT, JB, NS and SJ expressed and purified the proteins. KC, SJ and EC sequenced and expressed antibodies. EC and KC performed mutagenesis for mutant expression plasmids. ACW and S.B. performed binding assays. AR, AFP and CG contributed to donor’s recruitment and sample collection related to mAbs isolation. HWV, GS, AL, DV, LP, DV and DC analyzed the data and prepared the manuscript with input from all authors.

Competing interests

A.D.M., J.B., D.P., C.S.F., S.B., K.C., N.S., E.C., G.S., S.J., A.L., H.W.V., M.S.P., L.P. and D.C. are employees of Vir Biotechnology and may hold shares in Vir Biotechnology. H.W.V. is a founder of PierianDx and Casma Therapeutics. Neither company provided funding for this work or is performing related work. D.V. is a consultant for Vir Biotechnology Inc. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The
remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. RKG has received consulting fees from UMOVIS Lab, Gilead and ViiV.

MATERIALS AND METHODS
Participant recruitment and ethics
Participants who had received the first dose of vaccine and individuals with COVID-19 (Coronavirus Disease-19) were consented into the COVID-19 cohort of the NIHR Bioresource. The study was approved by the East of England – Cambridge Central Research Ethics Committee (17/EE/0025).

SARS-CoV-2 serology by multiplex particle-based flow cytometry (Luminex):
Recombinant SARS-CoV-2 N, S and RBD were covalently coupled to distinct carboxylated bead sets (Luminex; Netherlands) to form a 3-plex and analyzed as previously described (Xiong et al. 2020). Specific binding was reported as mean fluorescence intensities (MFI). Linear regression was used to explore the association between antibody response, T cell response and serum neutralisation in Stata 13. The Pearson correlation coefficient was reported.

Recombinant expression of SARS-CoV-2-specific mAbs.
Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV-2 immune donors, as previously described. Recombinant antibodies were expressed in ExpiCHO cells at 37°C and 8% CO₂. Cells were transfected using ExpiFectamine. Transfected cells were supplemented 1 day after transfection with ExpiCHO Feed and ExpiFectamine CHO Enhancer. Cell culture supernatant was collected eight days after transfection and filtered through a 0.2 μm filter. Recombinant antibodies were affinity purified on an ÄKTA xpress fast protein liquid chromatography (FPLC) device using 5 mL HiTrap™ MabSelect™ PrismA columns followed by buffer exchange to Histidine buffer (20 mM Histidine, 8% sucrose, pH 6) using HiPrep 26/10 desalting columns.

Generation of S mutants
Amino acid substitutions were introduced into the D614G pCDNA_SARS-CoV-2_S plasmid as previously described using the QuikChange Lightening Site-Directed Mutagenesis kit.
following the manufacturer’s instructions (Agilent Technologies, Inc., Santa Clara, CA).

Sequences were checked by Sanger sequencing.

Preparation of B.1.1.7 or TM SARS-CoV-2 S glycoprotein-encoding-plasmid used to produce SARS-CoV-2-MLV based on overlap extension PCR. Briefly, a modification of the overlap extension PCR protocol was used to introduce the nine mutations of the B.1.1.7 lineage or the three mutations in TM mutant in the SARS-CoV-2 S gene. In a first step, 9 DNA fragments with overlap sequences were amplified by PCR from a plasmid (pCMV1, Genlantis) encoding the full-length SARS-CoV-2 S gene (BetaCoV/Wuhan-Hu-1/2019, accession number mn908947). The mutations (del-69/70, del-144, N501Y, A570D, D614G, P681H, S982A, T716I and D1118H or K417N, E484K and N501Y) were introduced by amplification with primers with similar Tm. Deletion of the C-terminal 21 amino acids was introduced to increase surface expression of the recombinant S. Next, 3 contiguous overlapping fragments were fused by a first overlap PCR (step 2) using the utmost external primers of each set, resulting in 3 larger fragments with overlapping sequences. A final overlap PCR (step 3) was performed on the 3 large fragments using the utmost external primers to amplify the full-length S gene and the flanking sequences including the restriction sites KpnI and NotI. This fragment was digested and cloned into the expression plasmid pCMV1. For all PCR reactions the Q5 Hot Start High fidelity DNA polymerase was used (New England Biolabs Inc.), according to the manufacturer’s instructions and adapting the elongation time to the size of the amplicon. After each PCR step the amplified regions were separated on agarose gel and purified using Illustra GFX™ PCR DNA and Gel Band Purification Kit (Merck KGaA).

Pseudotype virus preparation

Viral vectors were prepared by transfection of 293T cells by using Fugene HD transfection reagent (Promega). 293T cells were transfected with a mixture of 11ul of Fugene HD, 1µg of pCDNAΔ19spike-HA, 1ug of p8.91 HIV-1 gag-pol expression vector, and 1.5µg of pCSFLW (expressing the firefly luciferase reporter gene with the HIV-1 packaging signal). Viral supernatant was collected at 48 and 72h after transfection, filtered through 0.45um filter and stored at -80°C. The 50% tissue culture infectious dose (TCID₅₀) of SARS-CoV-2 pseudovirus was determined using Steady-Glo Luciferase assay system (Promega).

Serum/plasma pseudotype neutralization assay
Spike pseudotype assays have been shown to have similar characteristics as neutralisation testing using fully infectious wild type SARS-CoV-2\textsuperscript{20}. Virus neutralisation assays were performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 spike pseudotyped virus expressing luciferase\textsuperscript{58}. Pseudotyped virus was incubated with serial dilution of heat inactivated human serum samples or sera from vaccinees in duplicate for 1h at 37°C. Virus and cell only controls were also included. Then, freshly trypsinized 293T ACE2/TMPRSS2 expressing cells were added to each well. Following 48h incubation in a 5% CO\textsubscript{2} environment at 37°C, luminescence was measured using the Steady-Glo or Bright-Glo Luciferase assay system (Promega). Neutralization was calculated relative to virus only controls. Dilution curves were presented as a mean neutralization with standard error of the mean (SEM). ID\textsubscript{50} values were calculated in GraphPad Prism. The ID\textsubscript{50} withing groups were summarised as a geometric mean titre and statistical comparison between groups were made with Wilcoxon ranked sign test. In addition, the impact of the mutations on the neutralising effect of the sera were expressed as fold change (FC) of ID\textsubscript{50} of the wild-type compared to mutant pseudotyped virus. Statistical difference in the mean FC between groups was determined using a 2-tailed t-test.

\textit{IFNγ FluoroSpot assays}

Frozen PBMCs were rapidly thawed, and the freezing medium was diluted into 10ml of TexMACS media (Miltenyi Biotech), centrifuged and resuspended in 10ml of fresh media with 10U/ml DNase (Benzonase, Merck-Millipore via Sigma-Aldrich), PBMCs were incubated at 37°C for 1h, followed by centrifugation and resuspension in fresh media supplemented with 5% Human AB serum (Sigma Aldrich) before being counted. PBMCs were stained with 2ul of each antibody: anti-CD3-fluorescein isothiocyanate (FITC), clone UCHT1; anti-CD4-phycocerythrin (PE), clone RPA-T4; anti-CD8a-peridinin-chlorophyll protein - cyanine 5.5 (PerCP Cy5.5), clone RPA-8a (all BioLegend, London, UK), LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific). PBMC phenotyping was performed on the BD Accuri C6 flow cytometer. Data were analysed with FlowJo v10 (Becton Dickinson, Wokingham, UK). 1.5 to 2.5 x 10\textsuperscript{5} PBMCs were incubated in pre-coated Fluorospot plates (Human IFNγ FLUOROSPOT (Mabtech AB, Nacka Strand, Sweden)) in triplicate with peptide mixes specific for Spike, Nucleocapsid and Membrane proteins of SARS-CoV-2 (final peptide concentration 1µg/ml/peptide, Miltenyi Biotech) and an unstimulated and positive control mix (containing anti-CD3 (Mabtech AB),
Staphylococcus Enterotoxin B (SEB), Phytohaemagglutinin (PHA) (all Sigma Aldrich)) at 37°C in a humidified CO2 atmosphere for 48 hours. The cells and medium were decanted from the plate and the assay developed following the manufacturer’s instructions. Developed plates were read using an AID iSpot reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot v7 software (Autoimmun Diagnostika GmbH, Strasberg, Germany). All data were then corrected for background cytokine production and expressed as spot forming units (SFU)/Million PBMC or CD3 T cells. The association between spike Tcell response, spike specific antibody response and serum neutralisation was determined using linear regression and the Pearson correlation coefficient between these variables were determined using Stata 13.

Ab discovery and recombinant expression
Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV or SARS-CoV-2 immune donors, as previously described. Recombinant antibodies were expressed in ExpiCHO cells at 37°C and 8% CO2. Cells were transfected using ExpiFectamine. Transfected cells were supplemented 1 day after transfection with ExpiCHO Feed and ExpiFectamine CHO Enhancer. Cell culture supernatant was collected eight days after transfection and filtered through a 0.2 µm filter. Recombinant antibodies were affinity purified on an ÄKTA xpress FPLC device using 5 mL HiTrap™ MabSelect™ PrismA columns followed by buffer exchange to Histidine buffer (20 mM Histidine, 8% sucrose, pH 6) using HiPrep 26/10 desalting columns.

MAbs pseudovirus neutralization assay
MLV-based SARS-CoV-2 S-glycoprotein-pseudotyped viruses were prepared as previously described (Pinto et al., 2020). HEK293T/17cells were cotransfected with a WT, B.1.1.7 or TM SARS-CoV-2 spike glycoprotein-encoding-plasmid, an MLV Gag-Pol packaging construct and the MLV transfer vector encoding a luciferase reporter using X-tremeGENE HP transfection reagent (Roche) according to the manufacturer’s instructions. Cells were cultured for 72 h at 37°C with 5% CO2 before harvesting the supernatant. VeroE6 stably expressing human TMPRSS2 were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin–streptomycin (100 I.U. penicillin/mL, 100 µg/mL), 8 µg/mL puromycin and plated into 96-well plates for 16–24 h. Pseudovirus with serial dilution of mAbs was incubated for 1 h at 37°C and then added to the wells after washing 2 times with DMEM. After 2–3 h DMEM containing 20% FBS and 2%
penicillin–streptomycin was added to the cells. Following 48-72 h of infection, Bio-Glo (Promega) was added to the cells and incubated in the dark for 15 min before reading luminescence with Synergy H1 microplate reader (BioTek). Measurements were done in duplicate and relative luciferase units were converted to percent neutralization and plotted with a non-linear regression model to determine IC50 values using GraphPad PRISM software (version 9.0.0).

**Antibody binding measurements using bio-layer interferometry (BLI)**

MAbs were diluted to 3 µg/ml in kinetic buffer (PBS supplemented with 0.01% BSA) and immobilized on Protein A Biosensors (FortéBio). Antibody-coated biosensors were incubated for 3 min with a solution containing 5 µg/ml of WT, N501Y or E484K SARS-CoV-2 RBD in kinetic buffer, followed by a 3-min dissociation step. Change in molecules bound to the biosensors caused a shift in the interference pattern that was recorded in real time using an Octet RED96 system (FortéBio). The binding response over time was used to calculate the area under the curve (AUC) using GraphPad PRISM software (version 9.0.0).

**Production of SARS-CoV-2 and B.1.1.7 receptor binding domains and human ACE2**

The SARS-CoV-2 RBD (BEI NR-52422) construct was synthesized by GenScript into CMVR with an N-terminal mu-phosphatase signal peptide and a C-terminal octa-histidine tag (GHHHHHHHHH) and an avi tag. The boundaries of the construct are N-328RFPN331 and 528KKST531-C59. The B.1.1.7 RBD gene was synthesized by GenScript into pCMVR with the same boundaries and construct details with a mutation at N501Y. These plasmids were transiently transfected into Expi293F cells using Expi293F expression medium (Life Technologies) at 37°C 8% CO2 rotating at 150 rpm. The cultures were transfected using PEI cultivated for 5 days. Supernatants were clarified by centrifugation (10 min at 4000xg) prior to loading onto a nickel-NTA column (GE). Purified protein was biotinylated overnight using BirA (Biotin ligase) prior to size exclusion chromatography (SEC) into phosphate buffered saline (PBS). Human ACE2-Fc (residues 1-615 with a C-terminal thrombin cleavage site and human Fc tag) were synthesized by Twist. Clarified supernatants were affinity purified using a Protein A column (GE LifeSciences) directly neutralized and buffer exchanged. The Fc tag was removed by thrombin cleavage in a reaction mixture containing 3 mg of recombinant ACE2-FC ectodomain and 10 µg of thrombin in 20 mM Tris-HCl pH8.0, 150 mM NaCl and 2.5 mM CaCl2. The reaction mixture was incubated at 25°C overnight and re-loaded on a Protein A column to remove uncleaved protein and the Fc tag. The cleaved protein was further
purified by gel filtration using a Superdex 200 column 10/300 GL (GE Life Sciences) equilibrated in PBS.

**Protein affinity measurement using bio-layer interferometry**

Biotinylated RBD (WT, N501Y, or TM) were immobilized at 5 ng/μL in undiluted 10X Kinetics Buffer (Pall) to SA sensors until a load level of 1.1nm. A dilution series of either monomeric ACE2 or Fab in undiluted kinetics buffer starting at 1000-50nM was used for 300-600 seconds to determine protein-protein affinity. The data were baseline subtracted and the plots fitted using the Pall FortéBio/Sartorius analysis software (version 12.0). Data were plotted in Prism.

**Statistical analysis**

Linear regression was used to explore the association between antibody response, T cell response and serum neutralisation in Stata 13. The Pearson correlation coefficient was reported.

**Neutralisation data analysis**

Neutralization was calculated relative to virus only controls. Dilution curves were presented as a mean neutralization with standard error of the mean (SEM). IC50 values were calculated in GraphPad Prism. The inhibitory dilution (ID50) within groups were summarised as a geometric mean titre and statistical comparison between groups were made with Wilcoxon ranked sign test. In addition, the impact of the mutations on the neutralising effect of the sera were expressed as fold change of ID50 of the wild-type compared to mutant pseudotyped virus. Statistical difference in the mean FC between groups was determined using a 2-tailed t-test

**IFNγ FluoroSpot assay data analysis**

The association between spike Tcell response, spike specific antibody response and serum neutralisation was determined using linear regression and the Pearson correlation coefficient between these variables were determined using Stata 13.

**Data availability.**

The neutralization and BLI data shown in Fig. 4 and Extended Data Fig. 5-7 can be found in Source Data Fig. 4. Other data are available from the corresponding author on request.
Table 1. Kinetic analysis of human ACE2 binding to SARS-CoV-2 Wuhan-1, N501Y and N501Y/ E484K/ K417N (TM) RBDs by biolayer interferometry. Values reported represent the global fit to the data shown in Extended Data Fig. 8.

<table>
<thead>
<tr>
<th></th>
<th>SARS-CoV-2 RBD WT</th>
<th>SARS-CoV-2 RBD N501Y</th>
<th>SARS-CoV-2 RBD TM</th>
</tr>
</thead>
<tbody>
<tr>
<td>$K_D$ (nM)</td>
<td>133</td>
<td>22</td>
<td>64</td>
</tr>
<tr>
<td>$k_{on}$ (M$^{-1}$.s$^{-1}$)</td>
<td>1.3*10$^3$</td>
<td>1.4*10$^5$</td>
<td>1.3*10$^5$</td>
</tr>
<tr>
<td>$k_{off}$ (s$^{-1}$)</td>
<td>1.8*10$^{-2}$</td>
<td>3*10$^{-3}$</td>
<td>8.5*10$^{-3}$</td>
</tr>
</tbody>
</table>

hACE2
<table>
<thead>
<tr>
<th>mAb</th>
<th>Domain (site)</th>
<th>VH usage (%)</th>
<th>Source (DSO)</th>
<th>IC50 WT (ng/ml)</th>
<th>IC50 B.1.1.7 (ng/ml)</th>
<th>ACE2 blocking</th>
<th>SARS-CoV</th>
<th>Escape residues</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4A8</td>
<td>NTD (i)</td>
<td>1-24</td>
<td>N/A</td>
<td>38</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>S12P; C136Y; Y144del; H146Y; K147T; R246A</td>
<td>50</td>
</tr>
<tr>
<td>S2L26</td>
<td>NTD (i)</td>
<td>1-24 (97.2)</td>
<td>Hosp. (52)</td>
<td>70</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>N/A</td>
<td>24</td>
</tr>
<tr>
<td>S2L50</td>
<td>NTD (i)</td>
<td>4-59 (95.4)</td>
<td>Hosp. (52)</td>
<td>264</td>
<td>50</td>
<td>Neg.</td>
<td>-</td>
<td>N/A</td>
<td>24</td>
</tr>
<tr>
<td>S2M28</td>
<td>NTD (i)</td>
<td>3-33 (97.6)</td>
<td>Hosp. (46)</td>
<td>295</td>
<td>12'207</td>
<td>Neg.</td>
<td>-</td>
<td>S95/Q; S12P; C15F/R; L18P; Y28C; A123T; C136Y; G142D; Y144del; K147Q/T; R246G; P521L; G252C</td>
<td>24</td>
</tr>
<tr>
<td>S2X107</td>
<td>NTD (i)</td>
<td>4-38-2 (97)</td>
<td>Sympt. (75)</td>
<td>388</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>N/A</td>
<td>24</td>
</tr>
<tr>
<td>S2X124</td>
<td>NTD (i)</td>
<td>3-30 (99)</td>
<td>Sympt. (75)</td>
<td>221</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>N/A</td>
<td>24</td>
</tr>
<tr>
<td>S2X158</td>
<td>NTD (i)</td>
<td>1-24 (96.3)</td>
<td>Sympt. (75)</td>
<td>56</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>N/A</td>
<td>24</td>
</tr>
<tr>
<td>S2X28</td>
<td>NTD (i)</td>
<td>3-30 (97.9)</td>
<td>Sympt. (48)</td>
<td>1'399</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>P9S; S12P; C15W; L18P; C136G/Y; F140S; L141S; G142CD; Y144CN; K147TQ/E; R158G; L244S; R246G</td>
<td>24</td>
</tr>
<tr>
<td>S2X303</td>
<td>NTD (i)</td>
<td>2-5 (95.9)</td>
<td>Sympt. (125)</td>
<td>69</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>N/A</td>
<td>24</td>
</tr>
<tr>
<td>S2X333</td>
<td>NTD (i)</td>
<td>3-33 (96.5)</td>
<td>Sympt. (125)</td>
<td>66</td>
<td>-</td>
<td>Neg.</td>
<td>-</td>
<td>P9L; S12P; C155Y; L18P; C136G/Y; F140C; G142D; K147T</td>
<td>24</td>
</tr>
<tr>
<td>S2D106</td>
<td>RBD (I/IRBM)</td>
<td>1-69 (97.2)</td>
<td>Hosp. (98)</td>
<td>27</td>
<td>20</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2D19</td>
<td>RBD (I/IRBM)</td>
<td>4-31 (99.7)</td>
<td>Hosp. (49)</td>
<td>128</td>
<td>75'200</td>
<td>Moderate</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2D32</td>
<td>RBD (I/IRBM)</td>
<td>3-49 (98.3)</td>
<td>Hosp. (49)</td>
<td>26</td>
<td>11</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2D65</td>
<td>RBD (I/IRBM)</td>
<td>3-9 (96.9)</td>
<td>Hosp. (49)</td>
<td>24</td>
<td>12</td>
<td>Weak</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2D8</td>
<td>RBD (I/IRBM)</td>
<td>3-23 (96.5)</td>
<td>Hosp. (49)</td>
<td>27</td>
<td>58'644</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2D97</td>
<td>RBD (I/IRBM)</td>
<td>2-5 (96.9)</td>
<td>Hosp. (98)</td>
<td>20</td>
<td>17</td>
<td>Weak</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2E11</td>
<td>RBD (I/IRBM)</td>
<td>4-61 (98.3)</td>
<td>Hosp. (51)</td>
<td>27</td>
<td>16</td>
<td>Weak</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2E12</td>
<td>RBD (I/IRBM)</td>
<td>1-58 (97.6)</td>
<td>Hosp. (51)</td>
<td>27</td>
<td>31</td>
<td>Strong</td>
<td>-</td>
<td>G476S (3x)</td>
<td>*;61</td>
</tr>
<tr>
<td>S2E13</td>
<td>RBD (I/IRBM)</td>
<td>1-18 (96.2)</td>
<td>Hosp. (51)</td>
<td>34</td>
<td>77</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2E16</td>
<td>RBD (I/IRBM)</td>
<td>3-30 (98.3)</td>
<td>Hosp. (51)</td>
<td>36</td>
<td>38</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2E23</td>
<td>RBD (I/IRBM)</td>
<td>3-64 (96.9)</td>
<td>Hosp. (51)</td>
<td>139</td>
<td>180</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2H14</td>
<td>RBD (I/IRBM)</td>
<td>3-15 (100)</td>
<td>Sympt. (17)</td>
<td>460</td>
<td>64'463</td>
<td>Weak</td>
<td>-</td>
<td>N/A</td>
<td>*;62</td>
</tr>
<tr>
<td>S2H19</td>
<td>RBD (I/IRBM)</td>
<td>3-15 (98.6)</td>
<td>Sympt. (17)</td>
<td>239</td>
<td>-</td>
<td>Weak</td>
<td>-</td>
<td>Y409N; L455F; E484K; E484Q; F490L; F490S; S404P</td>
<td>*;62</td>
</tr>
<tr>
<td>S2H58</td>
<td>RBD (I/IRBM)</td>
<td>1-2 (97.9)</td>
<td>Sympt. (45)</td>
<td>27</td>
<td>14</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2H7</td>
<td>RBD (I/IRBM)</td>
<td>3-66 (98.3)</td>
<td>Sympt. (17)</td>
<td>492</td>
<td>573</td>
<td>Weak</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2H70</td>
<td>RBD (I/IRBM)</td>
<td>1-2 (99)</td>
<td>Sympt. (45)</td>
<td>147</td>
<td>65</td>
<td>Weak</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2H71</td>
<td>RBD (I/IRBM)</td>
<td>2-5 (99)</td>
<td>Sympt. (45)</td>
<td>36</td>
<td>9</td>
<td>Moderate</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2M11</td>
<td>RBD (I/IRBM)</td>
<td>1-2 (96.5)</td>
<td>Hosp. (46)</td>
<td>11</td>
<td>4</td>
<td>Weak</td>
<td>-</td>
<td>Y409N; L455F; E484K; E484Q; F490L; F490S; S404P</td>
<td>*;62</td>
</tr>
<tr>
<td>S2N12</td>
<td>RBD (I/RBM)</td>
<td>4-39 (97.6)</td>
<td>Hosp. (51)</td>
<td>76</td>
<td>40</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2N22</td>
<td>RBD (I/RBM)</td>
<td>3-23 (96.5)</td>
<td>Hosp. (51)</td>
<td>32</td>
<td>21</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2N28</td>
<td>RBD (I/RBM)</td>
<td>3-30 (97.2)</td>
<td>Hosp. (51)</td>
<td>72</td>
<td>21</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X128</td>
<td>RBD (I/RBM)</td>
<td>1-69-2 (97.6)</td>
<td>Sympt. (75)</td>
<td>50</td>
<td>112</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X16</td>
<td>RBD (I/RBM)</td>
<td>1-69 (97.6)</td>
<td>Sympt. (48)</td>
<td>45</td>
<td>103</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X192</td>
<td>RBD (I/RBM)</td>
<td>1-69 (96.9)</td>
<td>Sympt. (75)</td>
<td>326</td>
<td>-</td>
<td>Weak</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X227</td>
<td>RBD (I/RBM)</td>
<td>1-46 (97.9)</td>
<td>Sympt. (75)</td>
<td>26</td>
<td>14</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X246</td>
<td>RBD (I/RBM)</td>
<td>3-48 (96.2)</td>
<td>Sympt. (75)</td>
<td>35</td>
<td>30</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X30</td>
<td>RBD (I/RBM)</td>
<td>1-69 (97.9)</td>
<td>Sympt. (48)</td>
<td>32</td>
<td>53</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X324</td>
<td>RBD (I/RBM)</td>
<td>2-5 (97.3)</td>
<td>Sympt. (125)</td>
<td>8</td>
<td>23</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X58</td>
<td>RBD (I/RBM)</td>
<td>1-46 (99)</td>
<td>Sympt. (48)</td>
<td>32</td>
<td>47</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2H90</td>
<td>RBD (II)</td>
<td>4-61 (96.6)</td>
<td>Sympt. (81)</td>
<td>77</td>
<td>32</td>
<td>Strong</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2H94</td>
<td>RBD (II)</td>
<td>3-23 (93.4)</td>
<td>Sympt. (81)</td>
<td>123</td>
<td>144</td>
<td>Strong</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2H97</td>
<td>RBD (V)</td>
<td>5-51 (98.3)</td>
<td>Sympt. (81)</td>
<td>513</td>
<td>248</td>
<td>Weak</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2K15</td>
<td>RBD (II)</td>
<td>2-26 (99.3)</td>
<td>Sympt. (87)</td>
<td>361</td>
<td>235</td>
<td>0</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2K21</td>
<td>RBD (II)</td>
<td>3-33 (96.2)</td>
<td>Sympt. (118)</td>
<td>201</td>
<td>189</td>
<td>0</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2K30</td>
<td>RBD (II)</td>
<td>1-2 (97.2)</td>
<td>Sympt. (87)</td>
<td>185</td>
<td>134</td>
<td>0</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2K63v2</td>
<td>RBD (II)</td>
<td>3-30-3 (95.6)</td>
<td>Sympt. (118)</td>
<td>144</td>
<td>215</td>
<td>0</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2L17</td>
<td>RBD (?)</td>
<td>5-10-1 (98.3)</td>
<td>Hosp. (51)</td>
<td>313</td>
<td>127</td>
<td>Moderate</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2L49</td>
<td>RBD (?)</td>
<td>2-70 (99.4)</td>
<td>Hosp. (51)</td>
<td>24</td>
<td>32</td>
<td>Neg.</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X259</td>
<td>RBD (IIa)</td>
<td>1-69 (94.1)</td>
<td>Sympt. (75)</td>
<td>145</td>
<td>91</td>
<td>Moderate</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X305</td>
<td>RBD (?)</td>
<td>1-2 (95.1)</td>
<td>Sympt. (125)</td>
<td>34</td>
<td>21</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X35</td>
<td>RBD (IIa)</td>
<td>1-18 (98.6)</td>
<td>Sympt. (48)</td>
<td>140</td>
<td>143</td>
<td>Strong</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X450</td>
<td>RBD (?)</td>
<td>2-26 (96.9)</td>
<td>Sympt. (271)</td>
<td>368</td>
<td>198</td>
<td>Strong</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X475</td>
<td>RBD (?)</td>
<td>3-21 (93.8)</td>
<td>Sympt. (271)</td>
<td>1'431</td>
<td>851</td>
<td>Strong</td>
<td>+</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X607</td>
<td>RBD (?)</td>
<td>3-66 (95.4)</td>
<td>Sympt. (271)</td>
<td>41</td>
<td>23</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X608</td>
<td>RBD (?)</td>
<td>1-33 (93.2)</td>
<td>Sympt. (271)</td>
<td>21</td>
<td>35</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X609</td>
<td>RBD (?)</td>
<td>1-69 (93.8)</td>
<td>Sympt. (271)</td>
<td>47</td>
<td>35</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X613</td>
<td>RBD (I)</td>
<td>1-2 (91.7)</td>
<td>Sympt. (271)</td>
<td>28</td>
<td>19</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X615</td>
<td>RBD (I)</td>
<td>3-11 (94.8)</td>
<td>Sympt. (271)</td>
<td>23</td>
<td>17</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X619</td>
<td>RBD (?)</td>
<td>1-69 (92.7)</td>
<td>Sympt. (271)</td>
<td>36</td>
<td>60</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
<tr>
<td>S2X620</td>
<td>RBD (?)</td>
<td>3-53 (95.1)</td>
<td>Sympt. (271)</td>
<td>34</td>
<td>45</td>
<td>Strong</td>
<td>-</td>
<td>N/A</td>
<td>*</td>
</tr>
</tbody>
</table>

id., identity. DSO, days after symptom onset. * as described in Piccoli et al and McCallum et al. N/A, not available; -, not neutralising
References


Gregson, J. et al. HIV-1 viral load is elevated in individuals with reverse transcriptase mutation M184V/I during virological failure of first line antiretroviral therapy and is associated with compensatory mutation L741. *Journal of Infectious Diseases* (2019).


The COVID-19 Genomics UK (COG-UK) Consortium

**Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation:**

Samuel C Robson 13.
Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools: Nicholas J Loman 41 and Thomas R Connor 10, 69.

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation: Tanya Golubchik 5.

Funding acquisition, Metadata curation, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation: Rocio T Martinez Nunez 42.

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, and Samples and logistics: Catherine Ludden 88.

Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and analysis: Sally Corden 69.

Funding acquisition, Leadership and supervision, Project administration, Samples and logistics, and Sequencing and analysis: Ian Johnston 99 and David Bonsall 5.

Funding acquisition, Leadership and supervision, Sequencing and analysis, Software and analysis tools, and Visualisation: Colin P Smith 87 and Ali R Awan 28.

Funding acquisition, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation: Giselda Bucca 87.

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and Sequencing and analysis: M. Estee Torok 22, 101.

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and Visualisation: Kordo Saeed 81, 110 and Jacqui A Prieto 83, 109.

Leadership and supervision, Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools: David K Jackson 99.
Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:
William L Hamilton 22.

Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Visualisation:

Funding acquisition, Leadership and supervision, Metadata curation, and Samples and logistics:
Catherine Moore 69.

Funding acquisition, Leadership and supervision, Project administration, and Samples and logistics:
Ewan M Harrison 99, 88.

Leadership and supervision, Metadata curation, Project administration, and Samples and logistics:
Sonia Goncalves 99.

Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and analysis:
Ian G Goodfellow 24, Derek J Fairley 3, 72, Matthew W Loose 18 and Joanne Watkins 69.

Leadership and supervision, Metadata curation, Samples and logistics, and Software and analysis tools:
Rich Livett 99.

Leadership and supervision, Metadata curation, Samples and logistics, and Visualisation:
Samuel Moses 25, 106.

Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis tools:
Roberto Amato 99, Sam Nicholls 41 and Matthew Bull 69.

Leadership and supervision, Project administration, Samples and logistics, and Sequencing and analysis:
Darren L Smith 37, 58, 105.

Leadership and supervision, Sequencing and analysis, Software and analysis tools, and Visualisation:
Jeff Barrett 99, David M Aanensen 14, 114.

Metadata curation, Project administration, Samples and logistics, and Sequencing and analysis:
Martin D Curran 65, Surendra Parmar 65, Dinesh Aggarwal 95, 99, 64 and James G Shepherd 48.
Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools:
Matthew D Parker 93.

Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:
Sharon Glaysher 61.

Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation:
Matthew Bashton 37. 58, Anthony P Underwood 14, 114, Nicole Pacchiarini 69 and Katie F Loveson 77.

Project administration, Sequencing and analysis, Software and analysis tools, and Visualisation:
Alessandro M Carabelli 88.

Funding acquisition, Leadership and supervision, and Metadata curation:
Kate E Templeton 53, 90.

Funding acquisition, Leadership and supervision, and Project administration:
Cordelia F Langford 99, John Sillitoe 99, Thushan I de Silva 93 and Dennis Wang 93.

Funding acquisition, Leadership and supervision, and Sequencing and analysis:
Dominic Kwiatkowski 99, 107, Andrew Rambaut 90, Justin O’Grady 70, 89 and Simon Cottrell 69.

Leadership and supervision, Metadata curation, and Sequencing and analysis:

Leadership and supervision, Project administration, and Samples and logistics:
Husam Osman 64, 36, Monique Andersson 59, Anoop J Chauhan 61 and Mohammed O Hassan-Ibrahim 6.

Leadership and supervision, Project administration, and Sequencing and analysis:
Mara Lawniczak 99.

Leadership and supervision, Samples and logistics, and Sequencing and analysis:

Leadership and supervision, Sequencing and analysis, and Software and analysis tools:

Leadership and supervision, Sequencing and analysis, and Visualisation:
Andrew R Bassett 99.
Metadata curation, Project administration, and Samples and logistics:

Metadata curation, Project administration, and Sequencing and analysis:
Martin P McHugh 53 and Rebecca Dewar 53.

Metadata curation, Samples and logistics, and Sequencing and analysis:
Aminu S Jahun 24, Claire McMurray 41, Sarojini Pandey 84, James P McKenna 3, Andrew Nelson 58, 105, Gregory R Young 37, 58, Clare M McCann 58, 105 and Scott Elliott 61.

Metadata curation, Samples and logistics, and Visualisation:
Hannah Lowe 25.

Metadata curation, Sequencing and analysis, and Software and analysis tools:
Ben Temperton 91, Sunando Roy 82, Anna Price 10, Sara Rey 69 and Matthew Wyles 93.

Metadata curation, Sequencing and analysis, and Visualisation:
Stefan Rooke 90 and Sharif Shaaban 68.

Project administration, Samples and logistics, Sequencing and analysis:
Mariateresa de Cesare 98.

Project administration, Samples and logistics, and Software and analysis tools:
Laura Letchford 99.

Project administration, Samples and logistics, and Visualisation:
Siona Silveira 81, Emanuela Pelosi 81 and Eleri Wilson-Davies 81.

Samples and logistics, Sequencing and analysis, and Software and analysis tools:
Myra Hosmillo 24.

Sequencing and analysis, Software and analysis tools, and Visualisation:

Funding acquisition, and Leadership and supervision:
Stephen L Michell 91, Dimitris Gramatopoulos 84, 112, Jonathan Edgeworth 12, Judith Breuer 30, 82, John A Todd 98 and Christophe Fraser 5.

Funding acquisition, and Project administration:
David Buck 98 and Michaela John 9.

Leadership and supervision, and Metadata curation:
Gemma L Kay 70.
Leadership and supervision, and Project administration:
Steve Palmer 99, Sharon J Peacock 88, 64 and David Heyburn 69.

Leadership and supervision, and Samples and logistics:
Danni Weldon 99, Esther Robinson 64, 36, Alan McNally 41, 86, Peter Muir 64, Ian B Vipond 64, John BoYes 29, Venkat Sivaprakasam 46, Tranprit Salluja 75, Samir Dervisevic 54 and Emma J Meader 54.

Leadership and supervision, and Sequencing and analysis:

Leadership and supervision, and Visualisation:
Jane AH Masoli 73, 91.

Metadata curation, and Samples and logistics:
Bridget A Knight 73, 91, Christopher R Jones 73, 91, Cherian Koshy 1, Amy Ash 1, Anna Casey 71, Andrew Bosworth 64, 36, Liz Ratcliffe 71, Li Xu-McCrae 36, Hannah M Pymont 64, Stephanie Hutchings 64, Lisa Berry 84, Katie Jones 84, Fenella Halstead 46, Thomas Davis 21, Christopher Holmes 16, Miren Iturriza-Gomara 92, Anita O Lucaci 92, Paul Anthony Randell 38, 104, Alison Cox 38, 104, Pinglawathee Madona 38, 104, Kathryn Ann Harris 30, Julianna Rose Brown 30, Tabitha W Mahungu 74, Dianne Irish-Tavares 74, Tanzina Haque 74, Jennifer Hart 74, Eric Witele 74, Melissa Louise Fenton 75, Steven Liggett 79, Clive Graham 56, Emma Swindells 57, Jennifer Collins 50, Gary Eltringham 50, Sharon Campbell 17, Patrick C McClure 97, Gemma Clark 15, Tim J Sloan 60, Carl Jones 15 and Jessica Lynch 2, 111.

Metadata curation, and Sequencing and analysis:
Ben Warne 8, Steven Leonard 99, Jillian Durham 99, Thomas Williams 90, Sam T Haldenby 92, Nathaniel Storey 30, Nabil-Fareed Alikhan 70, Nadine Holmes 18, Christopher Moore 18, Matthew Carlile 18, Malorie Perry 69, Noel Craine 69, Ronan A Lyons 80, Angela H Beckett 13, Salman Goudarzi 77, Christopher Fearn 77, Kate Cook 77, Hannah Dent 77 and Hannah Paul 77.

Metadata curation, and Software and analysis tools:
Robert Davies 99.

Project administration, and Samples and logistics:

Project administration, and Sequencing and analysis:
Nazreen F Hadjirin 88 and Joshua Quick 41.
Project administration, and Software and analysis tools:
Radoslaw Poplawski 41.

Samples and logistics, and Sequencing and analysis:

Samples and logistics, and Software and analysis tools:
Igor Starinskij 48.

Sequencing and analysis, and Software and analysis tools:

Software and analysis tools, and Visualisation:

Leadership and supervision:

Metadata curation:

Project administration:
Samples and logistics:

Danielle Leek 88, Sushmita Sridhar 88,99, Sally Forrest 88, Claire Cormie 88, Harmeet K Gill 88,
Joana Dias 88, Ellen E Higginson 88, Mailis Maes 88, Jamie Young 88, Michelle Wantoch 7,
Sanger Covid Team (www.sanger.ac.uk/covid-team) 99, Dorota Jamrozy 99, Stephanie Lo 99,
Minal Patel 95, Verity Hill 90, Claire M Bewshea 91, Sian Ellard 73, 91, Cressida Auckland 73, Ian
Harrison 66, Chloé Bishop 66, Vicki Chalker 66, Alex Richter 85, Andrew Beggs 85, Angus Best 86,
Benita Percival 86, Jeremy Mirza 86, Oliver Megram 86, Megan Mayhew 86, Liam Crawford 86,
Fiona Ashcroft 86, Emma Moles-Garcia 86, Nicola Cumley 86, Richard Hopes 64, Patawee
Asamaphan 48, Marc O Niebel 48, Rory N Gunson 100, Amanda Bradley 52, Alasdair Maclean 52,
Guy Mollett 52, Rachel Blacow 52, Paul Bird 16, Thomas Helmer 16, Karlie Fallon 16, Julian Tang
16, Antony D Hale 49, Louissa R Macfarlane-Smith 49, Katherine L Harper 49, Holli Carden 49,
Nicholas W Machin 45,64, Kathryn A Jackson 92, Shazaad S Y Ahmad 45,64, Ryan P George 45,
Lance Turtle 92, Elaine O'Toole 43, Joanne Watts 43, Cassie Breen 43, Angela Cowell 43, Adela
Alcolea-Medina 32,96, Themoula Charalampous 12,42, Amita Patel 11, Lisa J Levet 35, Judith
30, Adam P Westhorpe 82, Riaz Jannoo 82, Helen L Lowe 82, Angeliki Karamani 82, Leah Ensell
82, Wendy Chatterton 35, Monika Pusok 35, Ashok Dadrah 75, Amanda Symmonds 75, Graciela
Sluga 44, Zoltan Molnar 72, Paul Baker 79, Stephen Bonner 79, Sarah Essex 79, Edward Barton
56, Debra Padgett 56, Garren Scott 56, Jane Greenaway 57, Brendan Al Payne 50, Shirelle
Burton-Fanning 50, Sheila Waugh 50, Veena Raviprakash 17, Nicola Sheriff 17, Victoria Blakey
17, Lesley-Anne Williams 17, Jonathan Moore 27, Susanne Stonehouse 27, Louise Smith 55, Rose
K Davidson 89, Luke Bedford 26, Lindsay Coupland 54, Victoria Wright 18, Joseph G Chappell 97,
Theocharis Tsoleridis 97, Jonathan Ball 97, Manjinder Khakh 15, Vicki M Fleming 15, Michelle M
Lister 15, Hannah C Howson-Wells 15, Louise Berry 15, Tim Boswell 15, Amelia Joseph 15, Iona
Willingham 15, Nichola Duckworth 60, Sarah Walsh 60, Emma Wise 2,111, Nathan Moore 2,111,
Matilde Mori 2,108,111, Nick Cortes 2,111, Stephen Kidd 2,111, Rebecca Williams 33, Laura
Gifford 69, Kelly Bicknell 61, Sarah Wylie 61, Allyson Lloyd 61, Robert Impye 61, Cassandra S
Malone 6, Benjamin J Cogger 6, Nick Levene 62, Lynn Monaghan 62, Alexander J Keeley 93,
David G Partridge 78,93, Mohammad Raza 78,93, Cariad Evans 78,93 and Kate Johnson 78,93.

Sequencing and analysis:

Emma Betteridge 99, Ben W Farr 99, Scott Goodwin 99, Michael A Quail 99, Carol Scott 99,
Lesley Shirley 99, Scott AJ Thurston 99, Diana Rajan 99, Iraad F Bronner 99, Louise Aigrain 99,
Nicholas M Redshaw 99, Stefanie V Lensing 99, Shane McCarthy 99, Alex Makunin 99, Carlos E
Balcazar 90, Michael D Gallagher 90, Kathleen A Williamson 90, Thomas D Stanton 90, Michelle
L Michelsen 91, Joanna Warwick-Dugdale 91, Robin Manley 91, Audrey Farbos 91, James W
Harrison 91, Christine M Sambles 91, David J Studholme 91, Angie Lackenby 66, Tamyo Mbisa
66, Steven Platt 66, Shahjahan Miah 66, David Bibby 66, Carmen Manso 66, Jonathan Hubb 66,
Gavin Dabrera 66, Mary Ramsay 66, Daniel Bradshaw 66, Ulf Schaefer 66, Natalie Groves 66,
Eileen Gallagher 66, David Lee 66, David Williams 66, Nicholas Ellaby 66, Hassan Hartman 66,
Nikos Manesis 66, Vineet Patel 66, Juan Ledesma 67, Katherine A Twohig 67, Elias Allara 64,88,
Clare Pearson 64,88, Jeffrey K. J. Cheng 94, Hannah E. Bridgewater 94, Lucy R. Frost 94, Grace
Taylor-Joyce 94, Paul E Brown 94, Lily Tong 48, Alice Broos 48, Daniel Mair 48, Jenna Nichols 48,
Stephen N Carmichael 48, Katherine L Smollett 40, Kyriaki Nomikou 48, Elihu Aranday-Cortes
48, Natasha Johnson 48, Seema尼克巴克什 48,88, Edith E Vamos 92, Margaret Hughes 92,
Lucille Rainbow 92, Richard Eccles 92, Charlotte Nelson 92, Mark Whitehead 92, Richard
Gregory 92, Matthew Gemmell 92, Claudia Wierzbicki 92, Hermione J Webster 92, Chloe L
Software and analysis tools:


Visualisation:

Rob Johnson 39.
NHS Trust, 45 Manchester University NHS Foundation Trust, 46 Microbiology Department, Wye Valley NHS Trust, Hereford, 47 MRC Biostatistics Unit, University of Cambridge, 48 MRC-University of Glasgow Centre for Virus Research, 49 National Infection Service, PHE and Leeds Teaching Hospitals Trust, 50 Newcastle Hospitals NHS Foundation Trust, 51 Newcastle University, 52 NHS Greater Glasgow and Clyde, 53 NHS Lothian, 54 Norfolk and Norwich University Hospital, 55 Norfolk County Council, 56 North Cumbria Integrated Care NHS Foundation Trust, 57 North Tees and Hartlepool NHS Foundation Trust, 58 Northumbria University, 59 Oxford University Hospitals NHS Foundation Trust, 60 PathLinks, Northern Lincolnshire & Goole NHS Foundation Trust, 61 Portsmouth Hospitals University NHS Trust, 62 Princess Alexandra Hospital Microbiology Dept., 63 Public Health Agency, 64 Public Health England, 65 Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, UK, 66 Public Health England, Colindale, 67 Public Health England, Colindale, 68 Public Health Scotland, 69 Public Health Wales NHS Trust, 70 Quadram Institute Bioscience, 71 Queen Elizabeth Hospital, 72 Queen's University Belfast, 73 Royal Devon and Exeter NHS Foundation Trust, 74 Royal Free NHS Trust, 75 Sandwell and West Birmingham NHS Trust, 76 School of Biological Sciences, University of Portsmouth (PORT), 77 School of Pharmacy and Biomedical Sciences, University of Portsmouth (PORT), 78 Sheffield Teaching Hospitals, 79 South Tees Hospitals NHS Foundation Trust, 80 Swansea University, 81 University Hospitals Southampton NHS Foundation Trust, 82 University College London, 83 University Hospital Southampton NHS Foundation Trust, 84 University Hospitals Coventry and Warwickshire, 85 University of Birmingham, 86 University of Birmingham Turnkey Laboratory, 87 University of Brighton, 88 University of Cambridge, 89 University of East Anglia, 90 University of Edinburgh, 91 University of Exeter, 92 University of Liverpool, 93 University of Sheffield, 94 University of Warwick, 95 University of Cambridge, 96 Viapath, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, 97 Virology, School of Life Sciences, Queens Medical Centre, University of Nottingham, 98 Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, 99 Wellcome Sanger Institute, 100 West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde, 101 Department of Medicine, University of Cambridge, 102 Ministry of Health, Sri Lanka, 103 NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, 104 North West London Pathology, 105 NU-OMICS, Northumbria University, 106 University of Kent, 107 University of Oxford, 108 University of Southampton, 109 University of Southampton School of Health Sciences, 110 University of Southampton School of Medicine, 111 University of Surrey, 112 Warwick Medical School and Institute of Precision Diagnostics, Pathology, UHCW NHS Trust, 113 Wellcome Africa Health Research Institute Durban
Figure 1. Neutralization by first and second dose mRNA vaccine sera against wild type and B.1.1.7 Spike mutant SARS-CoV-2 pseudotyped viruses. a, Spike in open conformation with a single erect RBD (PDB: 6ZGG) in trimer axis vertical view with the locations of mutated residues highlighted in red spheres and labelled on the monomer with erect RBD. Vaccine first dose (b–c, n=37), second dose (d–e, n=21) and convalescent sera, Conv. (f–g, n=27) against WT and B.1.1.7 Spike mutant with N501Y, A570D, ΔH69/V70, Δ144/145, P681H, T716I, S982A and D1118H. GMT with s.d presented of two independent experiments each with two technical repeats. Wilcoxon matched-pairs signed rank test p-values: *<0.05, **<0.01, ***<0.001, ****<0.0001, ns not significant HS – human AB serum control. Limit of detection for 50% neutralization set at 10.
Figure 2. E484K appearing in background of B.1.1.7 with evidence of transmission a. Representation of Spike RBM:ACE2 interface (PDB: 6M0J) with residues E484, N501 and K417 highlighted as spheres coloured by element b. Maximum likelihood phylogeny of a subset of sequences from the United Kingdom bearing the E484K mutation (green) and lineage B.1.1.7 (blue), with background sequences without RBD mutations in black. As of 11th Feb 2021, 30 sequences from the B.1.1.7 lineage (one cluster of 25 at top of phylogenetic tree) have acquired the E484K mutation (red). c. Sequence accumulation over time in GISAID for UK sequences with B.1.1.7 and E484K. RBD – receptor binding domain; NTD – N terminal domain.
Figure 3. Neutralization potency of mRNA vaccine sera and convalescent sera (pre SARS-CoV-2 B.1.1.7) against pseudotyped virus bearing Spike mutations in the B1.1.7 lineage with and without E484K in the receptor binding domain (all In Spike D614G background). a, Example neutralization curves for vaccinated individuals. Data points represent mean of technical replicates with standard error and are representative of two independent experiments (b-g). 50% neutralisation titre for each virus against sera derived (b,c, n=37) following first vaccination (d,e, n=21) following second vaccination and (f,g, n=20) convalescent sera (CS) expressed as fold change relative to WT. Data points are mean fold change of technical replicates and are representative of two independent experiments. Central bar represents mean with outer bars representing s.d. Wilcoxon matched-pairs signed rank test p-values *<0.05, **<0.01, ***<0.001, ****<0.0001; ns not significant. Limit of detection for 50% neutralization set at 10.
Figure 4. Neutralization and binding by a panel of NTD- and RBD-specific mAbs against WT, B.1.1.7 and RBD mutant SARS-CoV-2 viruses. a, Neutralization of WT D614G (black), B.1.1.7 (blue) and a triple mutant (TM, carrying RBD mutations K417N/E484K/N501Y) (red) pseudotyped SARS-CoV-2-MLVs by 3 selected mAbs (S2E12, S2X333 and S2H14) from one representative experiment. Shown is the mean ± s.d. of 2 technical replicates. b, Neutralization of WT (D614G), B.1.1.7 and TM SARS-CoV-2-MLVs by 60 mAbs targeting NTD (n=10), RBM (n=31) and non-RBM sites in the RBD (n=19). Shown are the mean IC50 values (ng/ml) of n=2 independent experiments. c-e, Neutralization shown as mean IC50 values (upper panel) and mean fold change of B.1.1.7 (blue) or TM (red) relative to WT (lower panel) of NTD (c), RBM (d) and non-RBM (e) mAbs. Lower panel shows IC50 values from 2 independent experiments. f-h, Kinetics of binding of mAbs to WT (black), N501Y (blue) and E484K (red) RBD as measured by bio-layer interferometry (BLI). Shown in (f) are the 4 RBM-targeting mAbs with no reduced binding to N501Y or E484K RBD. Area under the curve (AUC) (g) and AUC fold change (h) of 50 mAbs tested against WT, N501Y and E484K RBD. mAbs with a >1.3 AUC fold change shown in blue and red. mAbs: monoclonal antibodies. NTD: N- terminal domain
Extended Data Figure 1: Immune responses three weeks after first dose of Pfizer SARS-CoV-2 vaccine BNT162b2

**a**, Serum IgG responses against N protein, Spike and the Spike Receptor Binding Domain (RBD) from first vaccine participants (green), recovered COVID-19 cases (red), 3 convalescent plasma units and healthy controls (grey) as measured by a flow cytometry based Luminex assay. MFI, mean fluorescence intensity. Geometric mean titre (GMT with standard deviation (s.d) of two technical repeats presented.

**b**, Relationship between serum IgG responses as measured by flow cytometry and serum neutralisation ID50. c, Relationship between serum neutralisation ID50 and T cell responses against SARS-CoV-2 by IFN gamma ELISpot. SFU: spot forming units. d, Relationship between serum IgG responses and T cell responses. Simple linear regression is presented with Pearson correlation (r), P-value (p) and regression coefficient/slope (β).
Extended data Fig. 2. Neutralization by first dose BNT162b2 vaccine and convalescent sera against wild type and mutant (N501Y, A570D, ΔH69/V70) SARS-CoV-2 pseudotyped viruses: (a-b) Vaccine sera dilution for 50% neutralization against WT and Spike mutant with N501Y, A570D, ΔH69/V70. Geometric mean titre (GMT) + s.d of two independent experiments with two technical repeats presented. (c-d) Convalescent sera dilution for 50% neutralization against WT and Spike mutant with N501Y, A570D, ΔH69/V70. GMT + s.d of representative experiment with two technical repeats presented. e, Representative curves of convalescent serum log_{10} inverse dilution against % neutralization for WT v N501Y, A570D, ΔH69/V70. Where a curve is shifted to the right this indicates the virus is less sensitive to the neutralizing antibodies in the serum. Data are means of technical replicates and error bars represent standard error of the mean. Data are representative of 2 independent experiments. Limit of detection for 50% neutralization set at 10.
Extended Data Fig. 3. Representative neutralization curves of BNT162b2 vaccine sera against pseudovirus virus bearing eight Spike mutations present in B.1.1.7 versus wild type (all In Spike D614G background). Indicated is serum log_{10} inverse dilution against % neutralization. Where a curve is shifted to the right this indicates the virus is less sensitive to the neutralizing antibodies in the serum. Data are for first dose of vaccine (D1). Data points represent means of technical replicates and error bars represent standard error of the mean. Limit of detection for 50% neutralization set at 10.
Extended Data Fig. 4. Representative neutralization curves of convalescent sera against wild type and B.1.1.7 Spike mutant SARS-CoV-2 pseudoviruses. Indicated is serum log_{10} inverse dilution against % neutralization. Where a curve is shifted to the right this indicates the virus is less sensitive to the neutralizing antibodies in the serum. Data points represent means of technical replicates and error bars represent standard error of the mean. Limit of detection for 50% neutralization set at 10.
Extended Data Fig. 5. Neutralisation of WT (D614G), B.1.1.7 and TM (N501Y, E484K, K417N) SARS-CoV-2 Spike pseudotyped virus by a panel of 57 monoclonal antibodies (mAbs). a-c, Neutralisation of WT (black), B.1.1.7 (blue) and TM (red) SARS-CoV-2-MLV by 9 NTD-targeting (a), 29 RBM-targeting (b) and 19 non-RBM-targeting (c) mAbs.
Extended Data Fig. 6. Kinetics of binding to WT and N501Y SARS-CoV-2 RBD of 43
RBD-specific mAbs. a-b, Binding to WT (black) and N501Y (blue) RBD by 22 RBM-
targeting (a) and 21 non-RBM-targeting (b) mAbs. An antibody of irrelevant specificity
was included as negative control. mAbs: monoclonal antibodies.
Extended Data Fig. 7. Kinetics of binding to WT and E484K SARS-CoV-2 RBD of 46 RBD-specific mAbs. a-b, Binding to WT (black) and E484K (red) RBD by 27 RBM-targeting (a) and 19 non-RBM-targeting (b) mAbs. An antibody of irrelevant specificity was included as negative control. mAbs: monoclonal antibodies.
Extended Data Fig. 8. Binding of human ACE2 to SARS-CoV-2 WT, N501Y, TM (N501Y, E484K, K417N) RBDs. a-b. BLI binding analysis of the human ACE2 ectodomain (residues 1-615) to immobilized SARS-CoV-2 WT RBD (a) and B.1.1.7 RBD (b). Black lines correspond to a global fit of the data using a 1:1 binding model. RBD: receptor binding domain.